China Pharma Holdings Stock Today
| CPHI Stock | USD 0.20 0.01 5.26% |
Performance0 of 100
| Odds Of DistressOver 64
|
China Pharma is trading at 0.2 as of the 21st of November 2024. This is a 5.26 percent increase since the beginning of the trading day. The stock's open price was 0.19. China Pharma has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for China Pharma Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of August 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of April 2002 | Category Healthcare | Classification Health Care |
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the Peoples Republic of China. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the Peoples Republic of China. The company has 19.25 M outstanding shares of which 93.6 K shares are currently shorted by private and institutional investors with about 0.22 trading days to cover. More on China Pharma Holdings
Moving together with China Stock
Moving against China Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
China Stock Highlights
| Chairman | Zhilin Li | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsChina Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand China Pharma's financial leverage. It provides some insight into what part of China Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
China Pharma Holdings (CPHI) is traded on NYSE MKT Exchange in USA. It is located in No. 17, Jinpan Road, Haikou, China, 570216 and employs 231 people. China Pharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.69 M. China Pharma Holdings conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 19.25 M outstanding shares of which 93.6 K shares are currently shorted by private and institutional investors with about 0.22 trading days to cover.
China Pharma Holdings currently holds about 2.24 M in cash with (699.69 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04.
Check China Pharma Probability Of Bankruptcy
Ownership AllocationChina Pharma holds a total of 19.25 Million outstanding shares. China Pharma Holdings retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check China Ownership Details
China Pharma Historical Income Statement
China Stock Against Markets
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.63 | Quarterly Revenue Growth (0.16) | Return On Assets (0.18) | Return On Equity (0.75) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.